Reshape Lifesciences Q2 Sales $2.25M Miss $2.61M Estimate
Portfolio Pulse from Benzinga Newsdesk
Reshape Lifesciences (NASDAQ:RSLS) reported Q2 sales of $2.25 million, missing the analyst consensus estimate of $2.61 million by 13.64 percent. This represents a 22.06 percent decrease compared to the same period last year.
August 07, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Reshape Lifesciences' Q2 sales fell short of analyst estimates by 13.64%, and decreased by 22.06% compared to the same period last year.
Reshape Lifesciences' Q2 sales not only missed analyst estimates, but also showed a significant year-over-year decrease. This could negatively impact investor sentiment and potentially lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100